GlassScriptPhysician profile
Michael C Alston
NPI 1326067224
$2,345.99
in general payments reported to CMS, 2019-2025
26 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $95.83 · 2021: $443 · 2022: $327 · 2023: $134 · 2024: $196 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $548.89 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.04 | 2019-2025 | Jardiance |
| Medtronic, INC. | $192.17 | 2025 | Micra |
| Lilly USA, LLC | $180.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $169.14 | 2019-2024 | Farxiga |
| Nestle Healthcare Nutrition INC. | $140.90 | 2021-2022 | |
| Pfizer INC. | $113.32 | 2019-2025 | |
| Abbott Laboratories | $65.43 | 2021-2023 | Jot Dx |
| Sanofi-Aventis U.S. LLC | $64.37 | 2019-2020 | |
| Dexcom, INC. | $58.88 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $56.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.73 | 2019-2021 | |
| Corcept Therapeutics | $48.89 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $43.86 | 2019 | |
| Sumitomo Pharma America, INC. | $36.36 | 2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.49 | 2021-2022 | |
| Stryker Corporation | $32.25 | 2022 | |
| Shield Therapeutics INC | $28.10 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.42 | 2024 | Lifevest |
| Phathom Pharmaceuticals, INC. | $19.29 | 2024 | Voquezna |
| Kyowa Kirin, INC. | $18.36 | 2024 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 2021 | |
| Amgen INC. | $16.51 | 2020 | |
| Abbvie INC. | $15.78 | 2025 | |
| Amarin Pharma, INC. | $14.23 | 2019 | |
| Glaxosmithkline, LLC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.